Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2003-05-15
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy and
safety of biphasic insulin aspart (NovoMix®30) to that of biphasic human insulin (Mixtard®
30) in subjects with type 2 diabetes.